Pembrolizumab with targeted radiation for limited head and neck spread
Treatments studied
Part of Cancer, Ear, nose & throat clinical trials.
This Phase 3 trial studies whether adding pembrolizumab (an immune medicine) to focused radiation (SABR) can better control head and neck cancer that has spread to only 1–5 spots. It may help some people live longer or delay cancer worsening by treating both the immune system and the specific metastases.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and can sign consent.
- Your head and neck cancer is confirmed as squamous cell cancer in certain areas (mouth, throat parts, voice box, or neck origin).
- You have limited spread to 1–5 metastases, and each spot can be treated with SABR (high-precision radiation).
- Tumor testing meets requirements: PD-L1 CPS is 1 or higher, and if your cancer is in the oropharynx, your HPV p16 test is checked.
- You can start first treatment for this spread, your disease is measurable on scans, and your functional status is good (ECOG 0–1).
- You’ve recovered from any prior treatment side effects to mild levels (about grade 0–1) and you are not needing steroid pills to control side effects.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether adding pembrolizumab (an immune system medicine) to radiation can improve outcomes in people newly diagnosed with metastatic head and neck squamous cell cancer. It may help the immune system better recognize and fight the cancer alongside radiation.
This trial studies whether pembrolizumab plus chemotherapy (platinum and gemcitabine) can control recurrent or metastatic head and neck squamous cell carcinoma that can’t be cured with local treatments. It may help shrink tumors and slow disease growth in people who haven’t had cancer medicines for this stage before.
This Phase 2 study tests pembrolizumab (an immunotherapy medicine) together with induction chemotherapy before the main cancer treatment for stage III/IVA head and neck squamous cell cancer. It aims to improve how well the tumor responds and how long people can stay controlled.
This trial tests a new way to give chemotherapy (pulsed doses) together with pembrolizumab (an immunotherapy) for people with head and neck cancer that has come back or spread and cannot be cured with local treatments. The goal is to see if this combination works better than standard approaches.
This trial tests whether pembrolizumab (an immunotherapy) combined with chemotherapy works better as a first treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) in the oral/throat area. It aims to improve cancer control and help people live longer with fewer side effects than standard care.
This trial tests whether pembrolizumab (an immunotherapy drug) works better than the usual chemo plus radiation after surgery for cancer that has come back in the head and neck area. It may help reduce cancer returning or spreading by using your immune system, but eligibility depends on how the cancer came back and your prior treatments.
Hear when a new Oligometastatic Squamous Cell Carcinoma of the Head and Neck trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.